Impact of baroreflex activation therapy on renal function - A pilot study

American Journal of Nephrology

Volumn 40, Issue 4, 2014, Pages 371-380

  Wallbach, Manuel ^a   Lehnig, Luca Yves ^a   Schroer, Charlotte ^a   Hasenfuss, Gerd ^a   Müller, Gerhard A ^a   Wachter, Rolf ^a   Koziolek, Michael J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Albuminuria; Baroreflex activation therapy; Hypertensive nephropathy; Proteinuria; Resistant hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; RENIN; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; SODIUM;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BAROREFLEX ACTIVATION THERAPY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MACROALBUMINURIA; MALE; MICROALBUMINURIA; OBSERVATIONAL STUDY; PILOT STUDY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RESISTANT HYPERTENSION; SODIUM EXCRETION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; HYPERTENSION; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; URINE;

AGED; ALDOSTERONE; BAROREFLEX; BLOOD PRESSURE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RENIN; SODIUM;

EID: 84909942743     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000368723     Document Type: Article

References (38)

1. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Re sults from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-773.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group: KDIGO cli nical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012; 2: 337-414.
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, W hite A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM: Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Educati on Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
4. Sarafidis PA, Bakris GL: Resistant hypertension: An overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-1757.
5. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, Kalantar-Zadeh K, Jacobsen SJ: Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013; 88: 1099-1107.
6. Sarafidis PA, Ruilope LM: Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: Time for re-evaluation? Kidney Int 2014; 85: 536-546.
7. Grassi G, Seravalle G, Brambilla G, Cesana F, Giannattasio C, Mancia G: Similarities and differences betwee n renal sympathetic denervation and carotid baroreceptor stimulation. Curr Vasc Pharmacol 2014; 12: 63-68 .
8. Ruilope LM, Bakris GL: Renal function and target organ damage in hypertension. Eur Heart J 2011; 32: 1599-1604.
9. Grassi G, Seravalle G, Dell'Oro R, Mancia G: Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep 2011; 13: 303-308.
10. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED: Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012; 59: 331-338.
11. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, Zoccali C: Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2620-2627.
12. Kiuchi MG, Maia GL, de Queiroz Carreira MA, Kiuchi T, Chen S, Andrea BR, Graciano ML, Lugon JR: Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J 2013; 34: 2114-2121.
13. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Sc hmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Bohm M: Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hyperte nsion. Hypertension 2012; 60: 419-424.
14. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW: Novel baroreflex activation therapy in resistant hypertension: Results of a European multicenter feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258.
15. Alnima T, de Leeuw PW, Tan FE, Kroon AA; Rheos Pivotal Trial Investigators: Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension. Hypertension 2013; 61: 1334-1339.
16. Doumas M, Faselis C, Tsioufis C, Papademetriou V: Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. Curr Hypertens Rep 2012; 14: 238-246.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, D etection, Evaluation, and Treatment of High Blood Pressure; National heart, lung, and blood institute; national high blood pressure education program coordinating committee: Seventh report of the Joint National Committee on Prevention, Detection , Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Back er G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zanna d F: 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2 013; 31: 1281-1357.
19. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient. Kidney Int 2012; 82: 840-856.
20. Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5 suppl 1):S1-S290.
21. Hoppe UC Brandt MC Wachter R Beige J Rump LC Kroon AA Cates AW Lovett EG Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood press ure with pacemaker-like safety profile: Results from the Barostim neo trial. J Am Soc Hypertens 2012 6 270-276.
22. Tordoir JH, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, Herold U, Irwin E, Kroon AA, de Leeuw P, Peters TK, Kieval R, Cody R: An implantable carotid sinus baroreflex activating system: Surgical technique and short-term outcome from a multicenter feasibility trial for the treatment of resistant h ypertension. Eur J Vasc Endovasc Surg 2007; 33: 414-421.
23. Howard JP, Nowbar AN, Francis DP: Size of blood pressure reduction from renal denervation: Insights from meta-analysis of antihypertensive d rug trials of 4,121 patients with focus on trial design: The CONVERGE report. Heart 2013; 99: 1579-1587.
24. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Sch midt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Bohm M: Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hyperten sion. Circulation 2013; 128: 132-140.
25. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.
26. Kawasaki T, Itoh K, Uezono K, Sasaki H: A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol 1993; 20: 7-14.
27. Kawamura M, Kusano Y, Takahashi T, Owada M, Sugawara T: Effectiveness of a spot urine method in evaluating daily salt intake in hypertensive patients taking oral antihypertensive drugs. Hyper tens Res 2006; 29: 397-402.
28. Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, Taal MW: Suboptimal blood pressure control in chronic kidney disease stage 3: Baseline data from a cohort study in primary care. BMC Fam Pract 2013; 14: 88.
29. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA: Prevalence of optimal treatment regim ens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013; 62: 691-697.
30. Cravedi P, Ruggenenti P, Remuzzi G: Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012; 8: 301-306.
31. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, S mith W, Bakris GL: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.
32. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Bohm M, Krum H: Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011; 100: 1049-1057.
33. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ: Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabet es and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499.
34. Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH: Renoprotection with and without blood pressure reduction. Kidney Int Suppl 2005:S54-S59.
35. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II A ntagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
36. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP: The role of sympathetic nervous activity in ren al injury and end-stage renal disease. Hypertens Res 2010; 33: 521-528.
37. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
38. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL: A controll ed trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.